【摘要】：目的系統(tǒng)評價比阿培南治療呼吸系統(tǒng)和泌尿系統(tǒng)細菌性感染的臨床療效和安全性。方法通過PubMed數(shù)據(jù)庫、ELSEVIER數(shù)據(jù)庫、相關(guān)期刊論文、萬方數(shù)據(jù)庫,檢索比阿培南治療呼吸系統(tǒng)和泌尿系統(tǒng)細菌性感染的臨床隨機對照試驗文獻,采用Rev Man 5.1版統(tǒng)計分析軟件進行Meta分析,采用GRADE profiler 3.6版軟件對證據(jù)質(zhì)量進行評價分級。結(jié)果共有9篇文獻符合納入標準,全部文獻共有患者1 397例,在總有效率[RR=1.04,95%CI(0.98,1.10),P=0.19]、細菌清除率[RR=1.02,95%CI(0.97,1.07),P=0.39]、呼吸系統(tǒng)細菌性感染有效率[RR=1.04,95%CI(0.97,1.11),P=0.26]、泌尿系統(tǒng)細菌性感染有效率[RR=0.98,95%CI(0.88,1.09),P=0.74]、總不良反應發(fā)生率[RR=0.83,95%CI(0.60,1.15),P=0.26]及各不良反應發(fā)生率方面,治療組(比阿培南)與對照組(亞胺培南/西司他丁鈉、美羅培南或其他碳青霉烯類抗菌藥物)均差異無統(tǒng)計學意義(P0.05)。GRADE系統(tǒng)評價結(jié)果顯示,總不良反應發(fā)生率和各不良反應發(fā)生率的證據(jù)水平為中等,其余各結(jié)局指標均為低級。結(jié)論基于當前的臨床證據(jù),比阿培南治療各種敏感菌所引起的呼吸系統(tǒng)和泌尿系統(tǒng)細菌性感染的有效性和安全性與美羅培南和亞胺培南/西司他丁相當。
[Abstract]:Objective to evaluate the efficacy and safety of Biapenem in the treatment of bacterial infections of respiratory and urinary systems. Methods the clinical randomized controlled trials of Biapenem in the treatment of bacterial infection of respiratory system and urinary system were searched by PubMed database, Chinese periodical full-text database and Wanfang database. The statistical analysis software of Rev Man 5.1 was used for Meta analysis, and the software GRADE profiler 3.6 was used to evaluate the quality of evidence. Results A total of 9 articles met the inclusion criteria, and 1,397 patients were included in all the literature. The total effective rate [RRN 1.04C _ (95) CI (0.981.10) P _ (0.19)], the bacterial clearance rate [RRN _ 1.02C _ (95) CI (0.971.07) P _ (0.39)], the effective rate of respiratory bacterial infection [(R _ (1.04) ~ (95) CI (0.971.11) P _ (0.26)], the effective rate of urinary system infection [RRN _ (0.9895) CI (0.88 鹵1.09) P _ (0.74)], the incidence of total adverse reactions [RR0.83C _ (95) CI (0.601.15)] and the incidence of adverse reactions were observed. There was no significant difference between the treatment group (Biapenem) and the control group (imipenem / cilastatin sodium, meropenem or other carbapenem antibiotics) (P0.05). The incidence of total adverse reactions and the incidence of adverse reactions were moderate, and the other outcome indicators were low. Conclusion based on current clinical evidence, Biapenem is as effective and safe as meropenem and imipenem / cilastatin in the treatment of bacterial infections of respiratory and urinary systems caused by various sensitive bacteria.
【作者單位】： 鄭州大學第一附屬醫(yī)院藥學部;
【分類號】：R56;R691.3

【相似文獻】

相關(guān)期刊論文 前9條

1 胡繩;肖貞良;田坤;連亨寧;;比阿培南治療全耐藥鮑曼不動桿菌肺炎體會[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2010年31期

2 覃永;龍勝澤;;國產(chǎn)比阿培南治療支氣管擴張癥合并細菌感染的療效觀察[J];重慶醫(yī)學;2011年16期

3 王丹鳳;唐良法;;比阿培南與亞胺培南/西司他丁治療下呼吸道感染療效對比[J];山東醫(yī)藥;2011年29期

4 閻曉路;董元洪;王晶;;國產(chǎn)比阿培南治療中度至重度呼吸道感染療效觀察[J];世界臨床藥物;2010年03期

5 惠復新;吳艷;汪家坤;;比阿培南治療重癥肺炎32例療效觀察[J];山東醫(yī)藥;2010年39期

6 楊帆;趙旭;吳菊芳;周新;修清玉;施毅;沈策;劉榮玉;張伯科;鐘玲;陳楠;倪兆慧;蘇炳華;吳n\;張嬰元;;比阿培南治療細菌性肺炎和尿路感染的多中心隨機對照臨床試驗[J];中國感染與化療雜志;2007年02期

7 吳艷;惠復新;范曉東;汪家坤;孫華;;比阿培南治療慢性阻塞性肺疾病急性加重期臨床評價[J];山東大學學報(醫(yī)學版);2010年09期

8 許蕾;王笑歌;李方治;劉朔;陳東紅;李晶;;國產(chǎn)比阿培南治療重度老年院內(nèi)獲得性肺炎61例[J];中國老年學雜志;2011年19期

9 高軍軍;常璇;袁軍;;高齡老年肺部感染應用比阿培南治療合并紅皮病1例[J];中華保健醫(yī)學雜志;2010年05期

，

本文編號：2180399